Literature DB >> 18981162

Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis.

Richard Ahrens1, Amanda Waddell, Luqman Seidu, Carine Blanchard, Rebecca Carey, Elizabeth Forbes, Maria Lampinen, Tara Wilson, Elizabeth Cohen, Keith Stringer, Edgar Ballard, Ariel Munitz, Huan Xu, Nancy Lee, James J Lee, Marc E Rothenberg, Lee Denson, Simon P Hogan.   

Abstract

Clinical studies have demonstrated a link between the eosinophil-selective chemokines, eotaxins (eotaxin-1/CCL11 and eotaxin-2/CCL24), eosinophils, and the inflammatory bowel diseases, Crohn's disease and ulcerative colitis (UC). However, the cellular source and individual contribution of the eotaxins to colonic eosinophilic accumulation in inflammatory bowel diseases remain unclear. In this study we demonstrate, by gene array and quantitative PCR, elevated levels of eotaxin-1 mRNA in the rectosigmoid colon of pediatric UC patients. We show that elevated levels of eotaxin-1 mRNA positively correlated with rectosigmoid eosinophil numbers. Further, colonic eosinophils appeared to be degranulating, and the levels positively correlated with disease severity. Using the dextran sodium sulfate (DSS)-induced intestinal epithelial injury model, we show that DSS treatment of mice strongly induced colonic eotaxin-1 and eotaxin-2 expression and eosinophil levels. Analysis of eosinophil-deficient mice defined an effector role for eosinophils in disease pathology. DSS treatment of eotaxin-2(-/-) and eotaxin-1/2(-/-) mice demonstrated that eosinophil recruitment was dependent on eotaxin-1. In situ and immunofluorescence analysis-identified eotaxin-1 expression was restricted to intestinal F4/80(+)CD11b(+) macrophages in DSS-induced epithelial injury and to CD68(+) intestinal macrophages and the basolateral compartment of intestinal epithelial cells in pediatric UC. These data demonstrate that intestinal macrophage and epithelial cell-derived eotaxin-1 plays a critical role in the regulation of eosinophil recruitment in colonic eosinophilic disease such as pediatric UC and provides a basis for targeting the eosinophil/eotaxin-1 axis in UC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981162      PMCID: PMC2728352          DOI: 10.4049/jimmunol.181.10.7390

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

1.  Activated eosinophils in inflammatory bowel disease: do they matter?

Authors:  P Desreumaux; S Nutten; J F Colombel
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

2.  A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation.

Authors:  S P Hogan; A Mishra; E B Brandt; M P Royalty; S M Pope; N Zimmermann; P S Foster; M E Rothenberg
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

Review 3.  Eotaxin and eosinophil recruitment: implications for human disease.

Authors:  S M Rankin; D M Conroy; T J Williams
Journal:  Mol Med Today       Date:  2000-01

4.  Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells.

Authors:  S Matsukura; C Stellato; J R Plitt; C Bickel; K Miura; S N Georas; V Casolaro; R P Schleimer
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

5.  Polarized secretion of CXC chemokines by human intestinal epithelial cells in response to Bacteroides fragilis enterotoxin: NF-kappa B plays a major role in the regulation of IL-8 expression.

Authors:  J M Kim; Y K Oh; Y J Kim; H B Oh; Y J Cho
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

6.  Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa.

Authors:  Konstantinos A Papadakis; John Prehn; Daocheng Zhu; Carol Landers; Joanne Gaiennie; Phillip R Fleshner; Stephan R Targan
Journal:  Inflamm Bowel Dis       Date:  2004-11       Impact factor: 5.325

7.  Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study.

Authors:  Subra Kugathasan; Robert H Judd; Raymond G Hoffmann; Janice Heikenen; Gregorz Telega; Farhat Khan; Sally Weisdorf-Schindele; William San Pablo; Jean Perrault; Roger Park; Michael Yaffe; Christopher Brown; Maria T Rivera-Bennett; Issam Halabi; Alfonso Martinez; Ellen Blank; Steven L Werlin; Colin D Rudolph; David G Binion
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

8.  Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival.

Authors:  Shunya Sasaki; Hiroyuki Yoneyama; Kenji Suzuki; Hidehisa Suriki; Tsuneo Aiba; Shiro Watanabe; Yusuke Kawauchi; Hiroshi Kawachi; Fujio Shimizu; Kouji Matsushima; Hitoshi Asakura; Shosaku Narumi
Journal:  Eur J Immunol       Date:  2002-11       Impact factor: 5.532

9.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

10.  The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids.

Authors:  Arne Egesten; Mette Eliasson; Anders I Olin; Jonas S Erjefält; Anders Bjartell; Per Sangfelt; Marie Carlson
Journal:  Int J Colorectal Dis       Date:  2007-08-17       Impact factor: 2.571

View more
  78 in total

1.  The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications.

Authors:  Tomer Adar; Shimon Shteingart; Ami Ben-Ya'acov; Ariella Bar-Gill Shitrit; Dan M Livovsky; Shimrit Shmorak; Mahmud Mahamid; Bernardo Melamud; Fiona Vernea; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-02-13       Impact factor: 3.199

2.  Exacerbation of oxazolone colitis by infection with the helminth Hymenolepis diminuta: involvement of IL-5 and eosinophils.

Authors:  Arthur Wang; Maria Fernando; Gabriella Leung; Van Phan; David Smyth; Derek M McKay
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

3.  Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11.

Authors:  Amanda Waddell; Richard Ahrens; Kris Steinbrecher; Burke Donovan; Marc E Rothenberg; Ariel Munitz; Simon P Hogan
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

4.  CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.

Authors:  Maria Lampinen; Amanda Waddell; Richard Ahrens; Marie Carlson; Simon P Hogan
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

5.  IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis.

Authors:  Carlo De Salvo; Xiao-Ming Wang; Luca Pastorelli; Benedetta Mattioli; Sara Omenetti; Kristine A Buela; Saleem Chowdhry; Rekha R Garg; Wendy A Goodman; Alex Rodriguez-Palacios; Dirk E Smith; Derek W Abbott; Fabio Cominelli; Giorgos Bamias; Wei Xin; James J Lee; Maurizio Vecchi; Theresa T Pizarro
Journal:  Am J Pathol       Date:  2016-02-22       Impact factor: 4.307

6.  TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function.

Authors:  Reena Rani; Alan G Smulian; David R Greaves; Simon P Hogan; De'Broski R Herbert
Journal:  Eur J Immunol       Date:  2011-05-27       Impact factor: 5.532

7.  Histologic Correlates of Clinical and Endoscopic Severity in Children Newly Diagnosed With Ulcerative Colitis.

Authors:  Brendan Boyle; Margaret H Collins; Zhu Wang; David Mack; Anne Griffiths; Cary Sauer; James Markowitz; Neal LeLeiko; David Keljo; Joel Rosh; Susan S Baker; Marian Pfefferkorn; Melvin Heyman; Ashish Patel; Robert Baldassano; Joshua Noe; Paul Rufo; Subra Kugathasan; Thomas Walters; Lee Denson; Jeffrey Hyams
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

8.  Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase.

Authors:  Stephen D Zucker; Megan E Vogel; Tammy L Kindel; Darcey L H Smith; Gila Idelman; Uri Avissar; Ganesh Kakarlapudi; Michelle E Masnovi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-09-17       Impact factor: 4.052

9.  Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart.

Authors:  Nicola L Diny; Xuezhou Hou; Jobert G Barin; Guobao Chen; Monica V Talor; Julie Schaub; Stuart D Russell; Karin Klingel; Noel R Rose; Daniela Čiháková
Journal:  Eur J Immunol       Date:  2016-10-25       Impact factor: 5.532

10.  Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype.

Authors:  Benjamin Click; Alyce M Anderson; Ioannis E Koutroubakis; Claudia Ramos Rivers; Dmitriy Babichenko; Jorge D Machicado; Douglas J Hartman; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Arthur Barrie; Sally E Wenzel; Miguel Regueiro; David G Binion
Journal:  Am J Gastroenterol       Date:  2017-11-07       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.